Mostrando 4 resultados de: 4
Publisher
Cancer Biology and Therapy(1)
Frontiers in Pharmacology(1)
Journal of Cancer Science and Therapy(1)
World Journal of Surgical Oncology(1)
Origen
scopus(4)
Anti-epidermal growth factor/epidermal growth factor receptor therapeutic anti-cancer drugs and the wound healing process
ReviewAbstract: Cutaneous wound healing is a complex process involving blood clotting, inflammation, tissue formatioPalabras claves:CETUXIMAB, Cimavax, Erlotinib, Gefitinib, Her-1 vaccine, nimotuzumab, PanitimumabAutores:Casacó Parada A.R., Fernández A., Fuente D., Ledón N., Tania CrombetFuentes:scopusEffect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF
ArticleAbstract: Background: The epidermal growth factor receptor (EGFR) signaling system is frequently unbalanced inPalabras claves:CIMAvax® EGF, EGF, eGFR, Wound healingAutores:Acosta Brooks S., Bárbara Wilkinson, Barroso Alvarez M.D.C., Carmen Elena Viada, Casacó Parada A.R., Crespo Diaz T., Fernández Lorente A., Martínez Pérez L.B., Neninger Vinageras E., Troche Concepción M.Fuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.Fuentes:scopusSystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab
ArticleAbstract: Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) rePalabras claves:animal model, CETUXIMAB, Epidermal growth factor receptor, General toxicity, H-R3, Monkeys, nimotuzumab, Skin toxicityAutores:Arteaga M.E., Ballester-Labrada A., Baro F., Boleda M., Casacó Parada A.R., Charro L., Fuentes D., García M., González B., González C., Hernández O., Ledón N., Macías A.E., Morales Y., Orphee R., Pardo B., Pérez A., Ramos M., Rodríguez V., Rodriquez L., Subirós N., Tania Crombet, Viña L.Fuentes:scopus